1	JOHN F. GREANEY Steven B. Kramer	
2	U.S. DEPARTMENT OF JUSTICE	
3	555 4th Street, N.W. Washington, D.C. 20001	
4	Telephone: (202) 724-8310	
. 5		
6		
7		
8	UNITED STATES D	
9	FOR THE EASTERN DISTRICT OF CALIFORNIA FRESNO DIVISION	
10	- *	
11		_)
12	UNITED STATES OF AMERICA,)
13	Plaintiff,)
14	V.) Civil No. CV-F-83-481 REC)
15	NATIONAL MEDICAL ENTERPRISES,) <u>COMPETITIVE IMPACT STATEMENT</u>)
16	INC., and NME HOSPITALS, INC.,	4/8/87
17	Defendants.)
18		_)
	The United States, pursuant t	o Section 2(b) of the
19	Antitrust Procedures and Penalties Act ("APPA"), 15 U.S.C.	
20	<pre>\$ 16(b)-(h), files this Competitive Impact Statement relative</pre>	
21	to the proposed final judgment su	
22		Durced for entry in chis
23	antitrust proceeding.	
24		
25		
26		
	11 I.	
FORM OBD-183 MAR 83		
*		

.....

×

ł

۴

1

5

1

4

1 I. Nature and Purpose of the Proceeding On October 31, 1983, the United States filed a civil 2 : 3 antitrust complaint under Section 15 of the Clayton Act, 15 U.S.C. § 25, challenging the December 30, 1982 acquisition of . 4 Modesto City Hospital by National Medical Enterprises, Inc. 5 ("NME"), through its subsidiary, NME Hospitals, Inc., as a 6 violation of Section 7 of the Clayton Act, 15 U.S.C. § 18. 7 The complaint (which was later amended) charged that the effect of 8 the acquisition may be substantially to lessen competition 9 among providers of general acute care hospital services in the 10 Modesto area market. The amended complaint sought defendants' 11 divestiture of Modesto City Hospital and an injunction against 12 any future acquisitions by defendants without prior notice to 13 the government or approval by the Court. 14

15 The government and the defendants have stipulated that the 16 proposed final judgment may be entered after compliance with 17 the APPA. Entry of the proposed final judgment would terminate 18 this action, except that the Court would retain jurisdiction to 19 construe, modify and enforce the proposed final judgment and to 20 punish violations of it.

21 II. Background Events

22 On December 30, 1982, NME, through its subsidiary, NME 23 Hospitals, Inc., acquired the assets of Modesto City Hospital, 24 of Modesto, California, from Modesto City Hospital, Inc., for 25 approximately \$8 million in cash. At the time of the 26 acquisition, NME also owned Doctors Medical Center, the largest

- 2 -

FORM OBD-183 MAR 83

1 hospital in Modesto. Before the acquisition, Doctors Medical Center directly competed with Modesto City Hospital in the 2 provision of general acute care hospital services in the 3 Modesto area market, 1/ an area which includes Modesto and most 4 of Stanislaus County, California (except the communities of 5 Turlock and Denair), as well as the communities of Ripon and 6 Escalon in southern San Joaquin County, California. This is 7 the geographic area from which the hospitals attract the vast 8 majority of their patients. 9

General acute care hospitals provide a broad range of 10 integrated and interrelated health care services, unduplicated 11 by any other health care provider. General acute care hospital 12 services include most complex surgical and diagnostic 13 procedures and many medical procedures requiring general 14 anesthesia or continuous monitoring of a patient's condition. 15 In many cases, these services can be safely, conveniently, and 16 17 | economically performed only in a hospital setting. These and other unique characteristics distinguish general acute care 18

19

20

21
<u>1</u>/ Defendants have since announced plans to consolidate
22 Modesto City Hospital with Doctors Medical Center. Under the consolidation, which is in progress, most of Modesto City
23 Hospital's general acute care services will be transferred to Doctors Medical Center and Modesto City Hospital will be
24 converted to alternative uses (including ambulatory care, geriatric medicine, and an expansion of its adolescent chemical
25 dependency unit).

- 3 -

FORM OBD-183 MAR 83

P

hospital services from services provided by other health care
 providers such as clinics, freestanding ambulatory surgery
 centers, and doctors' offices.

Prior to the defendants' acquisition of Modesto City 4 Hospital, the Modesto area market for the provision of general 5 acute care hospital services was highly concentrated. NME's 6 Doctors Medical Center controlled approximately 34 percent of 7 the licensed general acute care hospital beds, and Modesto City 8 Hospital had approximately 14 percent of the licensed hospital 9 beds. The remaining beds were divided among four other 10 hospital competitors. 11

As a result of the December 30, 1982 acquisition of Modesto 12 City Hospital by NME, Doctors Medical Center and Modesto City 13 Hospital are under the common control of NME, and NME controls 14 about half of the hospital beds in the Modesto area market. 15 The Herfindahl-Hirschman Index (a measure of market 16 concentration calculated by squaring the market share of each 17 firm competing in the market and then summing the resulting 18 numbers) rose at least 900 points, from 2376 to at least 3336, 19 a strong indication that the market became even more highly 20 concentrated as a consequence of the acquisition. 2/ 21

- 22
- 23

24 2/ As the amended complaint makes clear, the market shares of the hospitals can also be measured by annual inpatient days and by gross patient revenues. Under either measure, the post-merger HHI is in excess of 3800, and the change in the HHI
 26 exceeds 1100 points.

Based upon these and other facts, the amended complaint
 alleges that the effect of the defendants' acquisition of
 Modesto City Hospital may be substantially to lessen
 competition in the provision of general acute care hospital
 services in the Modesto area market in violation of Section 7
 of the Clayton Act.

7 The defendants have contested the government's case. They 8 have argued that the relevant product market not only includes general acute care hospital services, but also services 9 provided by other health care providers, such as doctors' 10 11 offices and ambulatory surgery centers. They have also argued that the relevant geographic market for the provision of these 12 services extends as far north as Stockton and as far south as 13 Merced, California. In the defendants' view, the relevant 14 market was unconcentrated before their acquisition of Modesto 15 City Hospital, and the acquisition only nominally increased 16 market concentration. 17

Trial of the case commenced on July 9, 1985. On July 18, 18 19 1985, during the presentation of the government's evidence, the presiding judge announced his intention to dismiss the case 20 with prejudice because of misconduct by government attorneys. 21 The dismissal order was entered on July 24, 1985. 22 United States v. National Medical Enterprises, Inc., 107 F.R.D. 628 23 24 (E.D. Cal. 1985). The government appealed, and on June 23, 1986, the Ninth Circuit vacated the dismissal of the action so 25 26 - 5 -

that the district court judge could reconsider the motion to
 dismiss pursuant to certain standards set out in the opinion.
 <u>Id.</u>, 792 F.2d 906, 914 (9th Cir. 1986). The Ninth Circuit's
 opinion was amended on September 9, 1986, and in late 1986 the
 case was returned to the district court for further proceedings.

6

III. Explanation of The Proposed Final Judgment

The government and the defendants have stipulated that the 7 | proposed final judgment may be entered by the Court at any time 8 after compliance with the APPA. The proposed final judgment 9 does not constitute an admission by any party as to any issue 10 of fact or law. Under the provisions of Section 2(e) of the 11 APPA, entry of the proposed final judgment is conditioned upon 12 a determination by the Court that it is in the public interest 13 to do so. 14

The proposed final judgment enjoins the defendants, for a 15 ten-year period after entry of the judgment, from acquiring any 16 general acute care hospital in the Modesto area market without 17 the prior approval of the Department of Justice or the Court. 18 Acquisitions having a significant adverse effect on competition 19 in this market can involve dollar amounts that do not require 20 reporting under the premerger reporting program created by 21 Section 7A of the Clayton Act, 15 U.S.C. § 18(a). The proposed 22 final judgment eliminates the possibility that defendants could 23 make such acquisitions without notice to the government for the 24 next ten years. Should the defendants seek Court approval of 25

26

- 6 -

such an acquisition, they must affirmatively demonstrate to the
 Court that the acquisition would not substantially lessen
 competition in any line of commerce in any section of the
 country.

5 The proposed judgment also requires the defendants to 6 produce to the Department upon request certain information 7 concerning their compliance with the judgment.

Remedies Available to Potential Private Litigants IV. 8 Section 4 of the Clayton Act (15 U.S.C. § 15) provides that 9 any person who has been injured as a result of conduct 10 prohibited by the antitrust laws may bring suit in federal 11 court to recover three times the damages the person has 12 suffered, as well as costs and reasonable attorney fees. 13 Entry of the final judgment will neither impair nor assist the 14 bringing of any private antitrust damage action. Under the 15 provisions of Section 5(a) of the Clayton Act (15 U.S.C. 16 § 16(a)), the final judgment has no prima facie effect in any 17 private lawsuit that may be brought against the defendants. 18 19

V.Procedures Available For Modification20of The Proposed Final Judgment

As provided by the APPA, any person wishing to comment upon
the final judgment may within the statutory 60-day comment
period submit written comments to John W. Clark, Chief,
Professions & Intellectual Property Section, Antitrust
Division, United States Department of Justice, 555 4th Street,

26

- 7 -

1 N.W., Room 9903, Washington, D.C. 20001. These comments and the Department's responses will be filed with the Court and 2 published in the Federal Register. All comments will be given 3 due consideration by the Department, which remains free to 4 withdraw its consent to the judgment at any time prior to 5 6 entry. The judgment provides that the Court retains jurisdiction over this action and that any party may apply to 7 the Court for any order necessary or appropriate for its 8 9 modification, interpretation, or enforcement.

10

1

VI. Alternatives to the Proposed Final Judgment

11 The government considered requiring the divestiture of an 12 NME-owned hospital but was unable to achieve that result in 13 negotiations, and it became apparent that divestiture could be 14 accomplished only after a successful completion of the 15 litigation.

Given the current posture of the case, it would not be 16 possible to reach the merits of the government's case until the 17 defendants' motion to dismiss for prosecutorial misconduct is 18 resolved. This could involve protracted litigation, which 19 would be costly and time consuming. Furthermore, once the 20 motion to dismiss is resolved, resumption of the trial on the 21 merits, together with possible appeals, would also require the 22 expenditure of significant time and resources in the face of 23 substantial uncertainty that the government ultimately would 24 succeed. The government had presented much of its case at the 25 - 8 -26

1	time the defendants made their motion to dismiss, and the	
2	course of the trial causes the government to be less confident	
3	of its ability to prevail on the merits than it was before the	
4	trial began. Even if the government were ultimately to prevail	
5	on the merits, there would be problems associated with	
6	obtaining adequate relief: as noted earlier, NME currently is	
7	in the process of consolidating Modesto City Hospital with	
8	Doctors Medical Center, which when completed will make it less	
9	certain that two viable independently competing hospitals could	
10	be recreated. Therefore, we concluded that the proposed Final	
11	Judgment was the best alternative available to the government	
12	at the current time and that its entry is in the public	
13	interest.	
14	VII. Determinative Materials and Documents	
15	There are no materials or documents that the government	
16	considered determinative in formulating the proposed final	
17	judgment. Accordingly, none are being filed with this	
18	Competitive Impact Statement.	
19	Dated:	
20	Respectfully submitted,	
21	John F. Breanly JOHN F. GREANEY	
22	JOHN F. GREANEY	
23		
24	STEVEN B. KRAMER	
25		

Attorneys United States Department of Justice Antitrust Division

26